Jane Street Group LLC Sells 5,109 Shares of Achieve Life Sciences, Inc. (NASDAQ:ACHV)

Jane Street Group LLC lowered its holdings in shares of Achieve Life Sciences, Inc. (NASDAQ:ACHV) by 25.5% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 14,891 shares of the biopharmaceutical company’s stock after selling 5,109 shares during the period. Jane Street Group LLC’s holdings in Achieve Life Sciences were worth $71,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. State Street Corp lifted its position in shares of Achieve Life Sciences by 6.8% in the 3rd quarter. State Street Corp now owns 431,520 shares of the biopharmaceutical company’s stock worth $2,045,000 after purchasing an additional 27,419 shares during the period. Verition Fund Management LLC bought a new position in shares of Achieve Life Sciences in the third quarter worth approximately $113,000. MetLife Investment Management LLC raised its holdings in shares of Achieve Life Sciences by 65.6% during the third quarter. MetLife Investment Management LLC now owns 14,993 shares of the biopharmaceutical company’s stock valued at $71,000 after purchasing an additional 5,939 shares during the last quarter. SG Americas Securities LLC purchased a new position in shares of Achieve Life Sciences during the third quarter valued at approximately $54,000. Finally, The Manufacturers Life Insurance Company purchased a new stake in Achieve Life Sciences during the second quarter valued at approximately $69,000. Institutional investors own 33.52% of the company’s stock.

Achieve Life Sciences Stock Up 4.1 %

NASDAQ:ACHV opened at $3.28 on Thursday. Achieve Life Sciences, Inc. has a fifty-two week low of $3.12 and a fifty-two week high of $5.59. The stock has a market capitalization of $112.80 million, a P/E ratio of -2.90 and a beta of 1.66. The company has a debt-to-equity ratio of 0.31, a quick ratio of 6.78 and a current ratio of 6.78. The company’s 50-day simple moving average is $4.11 and its 200-day simple moving average is $4.47.

Achieve Life Sciences (NASDAQ:ACHV) last released its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.36) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.10). During the same period in the prior year, the business posted ($0.34) EPS. On average, equities analysts anticipate that Achieve Life Sciences, Inc. will post -1.17 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on ACHV. RODMAN&RENSHAW raised shares of Achieve Life Sciences to a “strong-buy” rating in a research note on Thursday, November 14th. Raymond James initiated coverage on shares of Achieve Life Sciences in a research note on Friday, September 27th. They issued a “strong-buy” rating and a $20.00 target price on the stock. Finally, Rodman & Renshaw began coverage on shares of Achieve Life Sciences in a research note on Thursday, November 14th. They issued a “buy” rating and a $12.00 price target on the stock. Four research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $14.80.

Achieve Life Sciences Company Profile

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.